{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:56:52Z","timestamp":1776578212570,"version":"3.51.2"},"reference-count":341,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P300PB_171189"],"award-info":[{"award-number":["P300PB_171189"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012117","name":"Lady Tata Memorial Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00152","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T04:17:11Z","timestamp":1526617031000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Therapeutic Antibodies for Myeloid Neoplasms\u2014Current Developments and Future Directions"],"prefix":"10.3389","volume":"8","author":[{"given":"Christian M.","family":"Sch\u00fcrch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdllow","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, \u2018real-world\u2019 cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjh.12425","article-title":"Survival and cure of acute myeloid leukaemia in England, 1971\u20132006: a population-based study","volume":"162","author":"Shah","year":"2013","journal-title":"Br J Haematol"},{"key":"B8","article-title":"Prognosis of acute myeloid leukemia","volume-title":"UpToDate","author":"Schiffer","year":"2017"},{"key":"B9","article-title":"Induction therapy for acute myeloid leukemia in younger adults","volume-title":"UpToDate","author":"Larson","year":"2017"},{"key":"B10","article-title":"Acute myeloid leukemia: treatment and outcomes in older adults","volume-title":"UpToDate","author":"Larson","year":"2017"},{"key":"B11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/bmt.2017.61","article-title":"Allogeneic transplantation in primary refractory AML","volume":"52","author":"Ferguson","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/leu.2014.242","article-title":"Resistance prediction in AML: analysis of 4601 patients from MRC\/NCRI, HOVON\/SAKK, SWOG and MD Anderson Cancer Center","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"key":"B14","article-title":"Treatment of relapsed or refractory acute myeloid leukemia","volume-title":"UpToDate","author":"Larson","year":"2017"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/ajh.23498","article-title":"Outcome of older patients with acute myeloid leukemia in first relapse","volume":"88","author":"Sarkozy","year":"2013","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjh.12691","article-title":"Antibody therapy for acute myeloid leukaemia","volume":"164","author":"Gasiorowski","year":"2014","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/leu.2014.244","article-title":"Novel drugs for older patients with acute myeloid leukemia","volume":"29","author":"Montalban-Bravo","year":"2014","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"B23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11899-015-0255-4","article-title":"Targeting the microenvironment in acute myeloid leukemia","volume":"10","author":"Rashidi","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.canlet.2015.05.007","article-title":"Acute myeloid leukemia in the vascular niche","volume":"380","author":"Cogle","year":"2016","journal-title":"Cancer Lett"},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2040620715619307","article-title":"Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence","volume":"7","author":"Rashidi","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/ajcp\/89.1.76","article-title":"The use of monoclonal antibody Y1\/82A in the identification of acute myeloblastic and monocytic leukemias","volume":"89","author":"Davey","year":"1988","journal-title":"Am J Clin Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1365-2141.1989.tb00248.x","article-title":"IL-2 and myelopoiesis: IL-2 induces blast cell proliferation in some cases of acute myeloid leukaemia","volume":"73","author":"Carron","year":"1989","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.7326\/0003-4819-116-2-148","article-title":"The multichain interleukin-2 receptor: a target for immunotherapy","volume":"116","author":"Waldmann","year":"1992","journal-title":"Ann Intern Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.leukres.2005.06.007","article-title":"Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing","volume":"30","author":"Koon","year":"2006","journal-title":"Leuk Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.ejca.2009.02.021","article-title":"Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML","volume":"45","author":"Terwijn","year":"2009","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1182\/blood-2012-02-414425","article-title":"CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900","volume":"120","author":"Gonen","year":"2012","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjh.12109","article-title":"Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML)","volume":"160","author":"Cerny","year":"2013","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17ra19","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/onc.2010.511","article-title":"Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells","volume":"30","author":"Majeti","year":"2011","journal-title":"Oncogene"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1182\/blood-2013-07-517847","article-title":"The IL-2\/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells","volume":"123","author":"Kobayashi","year":"2014","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/blood.V124.21.4491.4491","article-title":"Pre-clinical activity of Adct-301, a novel pyrrolobenzodiazepine (PBD) dimer-containing antibody drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"124","author":"Flynn","year":"2014","journal-title":"Blood"},{"key":"B38","first-page":"1510","article-title":"Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed\/refractory Hodgkin\/non-Hodgkin lymphoma","volume":"130","author":"Horwitz","year":"2017","journal-title":"Blood"},{"key":"B39","first-page":"2662","article-title":"Results from an ongoing phase 1 study indicate ACDT-301 (camidanlumab tesirine) is well-tolerated in patients with relapsed or refractory CD25-positive acute leukemia","volume":"130","author":"Goldberg","year":"2017","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1600-065X.2009.00774.x","article-title":"Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology","volume":"229","author":"Nolte","year":"2009","journal-title":"Immunol Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1074-7613(00)80172-7","article-title":"Expression of CD27 on murine hematopoietic stem and progenitor cells","volume":"12","author":"Wiesmann","year":"2000","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI45977","article-title":"CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression","volume":"122","author":"Sch\u00fcrch","year":"2012","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/ni1174","article-title":"Immune activation modulates hematopoiesis through interactions between CD27 and CD70","volume":"6","author":"Nolte","year":"2005","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors","volume":"35","author":"Burris","year":"2017","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev-immunol-020711-075018","article-title":"Siglecs and immune regulation","volume":"30","author":"Pillai","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B49","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","first-page":"E1660","DOI":"10.3390\/ijms18081660","article-title":"Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment","volume":"18","author":"Gbolahan","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-319-53156-4_4","article-title":"Harnessing the immune system against leukemia: monoclonal antibodies and checkpoint strategies for AML","volume":"995","author":"Masarova","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1182\/blood-2004-07-2784","article-title":"Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity","volume":"105","author":"Walter","year":"2005","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Olombel","year":"2016","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III children\u2019s oncology group trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/leu.2016.309","article-title":"Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia","volume":"31","author":"Khan","year":"2017","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III children\u2019s oncology group trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/ajh.21723","article-title":"Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)","volume":"85","author":"Middeldorf","year":"2010","journal-title":"Am J Hematol"},{"key":"B65","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V126.23.1307.1307","article-title":"HFE gene mutation status predicts response to gemtuzumab ozogamicin in AML","volume":"126","author":"Paubelle","year":"2015","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1080\/10428190903050013","article-title":"Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial","volume":"50","author":"Raza","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3324\/haematol.2012.066613","article-title":"Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2015-11-680546","article-title":"Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts","volume":"127","author":"Vasu","year":"2016","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1158\/1535-7163.MCT-16-0251","article-title":"In vitro and in vivo efficacy of a novel CD33-targeted thorium-227 conjugate for the treatment of acute myeloid leukemia","volume":"15","author":"Hagemann","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.V124.21.623.623","article-title":"Interim analysis of a phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML)","volume":"124","author":"Stein","year":"2014","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V126.23.454.454","article-title":"SGN-CD33A plus hypomethylating agents: a novel, well-tolerated regimen with high remission rate in frontline unfit AML","volume":"126","author":"Fathi","year":"2015","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood.V126.23.324.324","article-title":"A phase 1 trial of SGN-CD33A as monotherapy in patients with CD33-positive acute myeloid leukemia (AML)","volume":"126","author":"Stein","year":"2015","journal-title":"Blood"},{"key":"B75","unstructured":"RobinsonB Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia2017"},{"key":"B76","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1146\/annurev.immunol.21.120601.140946","article-title":"CD45: a critical regulator of signaling thresholds in immune cells","volume":"21","author":"Hermiston","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1182\/blood-2014-12-617019","article-title":"Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment","volume":"127","author":"Orozco","year":"2016","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.bbmt.2014.05.014","article-title":"Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Mawad","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B79","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood.V130.Suppl_1.910.910","article-title":"A phase I trial of 90Y-BC8-DOTA (anti-CD45) monoclonal antibody in combination with fludarabine and TBI as conditioning for allogeneic peripheral blood stem cell transplant to treat high risk multiple myeloma","volume":"130","author":"Tuazon","year":"2017","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1016\/j.bbmt.2017.12.227","article-title":"Safety and efficacy of escalating doses of 90Y-BC8-DOTA (anti-CD45) followed by carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy and autologous stem cell transplantation (ASCT) for high-risk lymphoma","volume":"24","author":"Cassaday","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B81","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3389\/fimmu.2017.00892","article-title":"CD56 in the immune system: more than a marker for cytotoxicity?","volume":"8","author":"Van Acker","year":"2017","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood.V90.4.1643","article-title":"Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22)","volume":"90","author":"Baer","year":"1997","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/sj.leu.2402174","article-title":"CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis","volume":"15","author":"Raspadori","year":"2001","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00432-015-1977-3","article-title":"Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis","volume":"141","author":"Xu","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.hemonc.2015.11.006","article-title":"CD56 and RUNX1 isoforms in AML prognosis and their therapeutic potential","volume":"9","author":"Zaidi","year":"2016","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lfs.2014.10.013","article-title":"CD123 and its potential clinical application in leukemias","volume":"122","author":"Liu","year":"2015","journal-title":"Life Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"B88","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","article-title":"Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells","volume":"123","author":"Nievergall","year":"2014","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/leu.2014.128","article-title":"Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC","volume":"28","author":"Busfield","year":"2014","journal-title":"Leukemia"},{"key":"B91","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V124.21.120.120","article-title":"First-in man, phase 1 study of CSL362 (anti-IL3R\u03b1\/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse","volume":"124","author":"Smith","year":"2014","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1182\/blood.V126.23.3819.3819","article-title":"Minimal residual disease (MRD) as exploratory endpoint in a phase 1 study of the anti-CD123 mab CSL362 given as post-remission therapy in adult acute myeloid leukemia (AML)","author":"Smith","year":"2015","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1182\/blood.V126.23.1370.1370","article-title":"Preclinical evaluation of CSL362\/JNJ-56022473 single agent in in vitro assays","volume":"126","author":"Syed","year":"2015","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood.V126.23.1370.1370","article-title":"Preclinical evaluation of CSL362\/JNJ-56022473 in combination with decitabine or azacitidine in in vitro assays","volume":"126","author":"Syed","year":"2015","journal-title":"Blood"},{"key":"B95","unstructured":"CourtE Johnson & Johnson Discards Two Hoped-for Billion-Dollar Drugs2017"},{"key":"B96","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, A potent CD123-directed antibody-drug conjugate for acute myeloid leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B97","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V126.23.1349.1349","article-title":"First preclinical report of the efficacy and PD results of KHK2823, a non-fucosylated fully human monoclonal antibody against IL-3R\u03b1","volume":"126","author":"Akiyama","year":"2015","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood.V128.22.2832.2832","article-title":"IMGN632: a CD123-targeting antibody-drug conjugate (ADC) with a novel DNA-alkylating payload, is highly active and prolongs survival in acute myeloid leukemia (AML) xenograft models","volume":"128","author":"Adams","year":"2016","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood.V128.22.768.768","article-title":"A CD123-targeting antibody-drug conjugate (ADC), IMGN632, designed to eradicate acute myeloid leukemia (AML) cells while sparing normal bone marrow cells","volume":"128","author":"Kovtun","year":"2016","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nri2726","article-title":"Awakening dormant haematopoietic stem cells","volume":"10","author":"Trumpp","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nature09262","article-title":"Mesenchymal and haematopoietic stem cells form a unique bone marrow niche","volume":"466","author":"Mendez-Ferrer","year":"2010","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-032712-095919","article-title":"Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine","volume":"31","author":"Frenette","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nature02040","article-title":"Osteoblastic cells regulate the haematopoietic stem cell niche","volume":"425","author":"Calvi","year":"2003","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nature02041","article-title":"Identification of the haematopoietic stem cell niche and control of the niche size","volume":"425","author":"Zhang","year":"2003","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature12612","article-title":"Arteriolar niches maintain haematopoietic stem cell quiescence","volume":"502","author":"Kunisaki","year":"2013","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"B108","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain haematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature11885","article-title":"Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches","volume":"495","author":"Ding","year":"2013","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature15250","article-title":"Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal","volume":"526","author":"Acar","year":"2015","journal-title":"Nature"},{"key":"B111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nri3132","article-title":"The bone marrow at the crossroads of blood and immunity","volume":"12","author":"Mercier","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1182\/blood-2011-12-380113","article-title":"Demand-adapted regulation of early hematopoiesis in infection and inflammation","volume":"119","author":"Takizawa","year":"2012","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nri3660","article-title":"Emergency granulopoiesis","volume":"14","author":"Manz","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nm.3155","article-title":"Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration","volume":"19","author":"Lucas","year":"2013","journal-title":"Nat Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nm.3647","article-title":"Hematopoietic stem cell niche maintenance during homeostasis and regeneration","volume":"20","author":"Mendelson","year":"2014","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nri2727","article-title":"Organization of immunological memory by bone marrow stroma","volume":"10","author":"Tokoyoda","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/nm914","article-title":"Bone marrow as a priming site for T-cell responses to blood-borne antigen","volume":"9","author":"Feuerer","year":"2003","journal-title":"Nat Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/cdd.2014.89","article-title":"Regulation of hematopoietic and leukemic stem cells by the immune system","volume":"22","author":"Riether","year":"2015","journal-title":"Cell Death Differ"},{"key":"B119","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"B120","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrc1592","article-title":"Leukaemia stem cells and the evolution of cancer-stem-cell research","volume":"5","author":"Huntly","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.cell.2007.05.014","article-title":"A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency","volume":"129","author":"Walkley","year":"2007","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2007.03.055","article-title":"Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment","volume":"129","author":"Walkley","year":"2007","journal-title":"Cell"},{"key":"B123","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature12883","article-title":"Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts","volume":"506","author":"Kode","year":"2014","journal-title":"Nature"},{"key":"B124","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature08851","article-title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia","volume":"464","author":"Raaijmakers","year":"2010","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1172\/JCI77347","article-title":"IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms","volume":"125","author":"Mager","year":"2015","journal-title":"J Clin Invest"},{"key":"B126","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"key":"B127","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.stem.2014.06.020","article-title":"Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche","volume":"15","author":"Hanoun","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B128","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B129","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2014.02.014","article-title":"Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit","volume":"14","author":"Medyouf","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B130","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ccr.2014.04.015","article-title":"Leukemia propagating cells rebuild an evolving niche in response to therapy","volume":"25","author":"Duan","year":"2014","journal-title":"Cancer Cell"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccell.2016.10.003","article-title":"CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia","volume":"30","author":"Bajaj","year":"2016","journal-title":"Cancer Cell"},{"key":"B133","first-page":"664","article-title":"Stimulation of proliferation and differentiation of acute myeloid leukemia cells on a bone marrow stroma in culture","volume":"13","author":"Scholzel","year":"1985","journal-title":"Exp Hematol"},{"key":"B134","first-page":"1252","article-title":"Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells","volume":"22","author":"Bendall","year":"1994","journal-title":"Exp Hematol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"key":"B136","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.8342023","article-title":"Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins","volume":"261","author":"Tashiro","year":"1993","journal-title":"Science"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1073\/pnas.91.6.2305","article-title":"Molecular cloning and structure of a pre-B-cell growth-stimulating factor","volume":"91","author":"Nagasawa","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B138","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/381661a0","article-title":"Identification of a major co-receptor for primary isolates of HIV-1","volume":"381","author":"Deng","year":"1996","journal-title":"Nature"},{"key":"B139","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/stem.2054","article-title":"Concise review: CXCR4\/CXCL12 signaling in immature hematopoiesis \u2013 lessons from pharmacological and genetic models","volume":"33","author":"Karpova","year":"2015","journal-title":"Stem Cells"},{"key":"B141","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fimmu.2015.00301","article-title":"CXCL12\/SDF-1 and CXCR4","volume":"6","author":"Nagasawa","year":"2015","journal-title":"Front Immunol"},{"key":"B142","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1182\/blood.V91.12.4523","article-title":"The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1","volume":"91","author":"Mohle","year":"1998","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1046\/j.1365-2141.2003.04466.x","article-title":"CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis)","volume":"122","author":"Burger","year":"2003","journal-title":"Br J Haematol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1182\/blood-2006-05-024844","article-title":"CXCR4 is a prognostic marker in acute myelogenous leukemia","volume":"109","author":"Spoo","year":"2007","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2008.238","article-title":"The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation","volume":"22","author":"Tavor","year":"2008","journal-title":"Leukemia"},{"key":"B146","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100","volume":"113","author":"Nervi","year":"2009","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1038\/bcj.2017.21","article-title":"A phase 1\/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia","volume":"7","author":"Uy","year":"2017","journal-title":"Blood Cancer J"},{"key":"B150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V124.21.386.386","article-title":"Targeting the CXCR4 pathway: safety, tolerability and clinical activity of ulocuplumab (BMS-936564), an anti-CXCR4 antibody, in relapsed\/refractory acute myeloid leukemia","volume":"124","author":"Becker","year":"2014","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V124.21.2311.2311","article-title":"A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematological malignancies","volume":"124","author":"Pernasetti","year":"2014","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation","volume":"12","author":"Roccaro","year":"2015","journal-title":"Cell Rep"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.18632\/oncotarget.6465","article-title":"Ulocuplumab (BMS-936564\/MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"B154","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13045-017-0435-x","article-title":"Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF06747143) in chronic lymphocytic leukemia","volume":"10","author":"Kashyap","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1182\/bloodadvances.2016003921","article-title":"A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies","volume":"1","author":"Liu","year":"2017","journal-title":"Blood Adv"},{"key":"B156","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1038\/s41598-017-07848-8","article-title":"Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"B157","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/36349","article-title":"Complementation of dominant suppression implicates CD98 in integrin activation","volume":"390","author":"Fenczik","year":"1997","journal-title":"Nature"},{"key":"B158","doi-asserted-by":"publisher","first-page":"8746","DOI":"10.1074\/jbc.M011239200","article-title":"Distinct domains of CD98hc regulate integrins and amino acid transport","volume":"276","author":"Fenczik","year":"2001","journal-title":"J Biol Chem"},{"key":"B159","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1073\/pnas.0404852102","article-title":"CD98hc (SLC3A2) mediates integrin signaling","volume":"102","author":"Feral","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B160","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1083\/jcb.200705090","article-title":"CD98hc (SLC3A2) participates in fibronectin matrix assembly by mediating integrin signaling","volume":"178","author":"Feral","year":"2007","journal-title":"J Cell Biol"},{"key":"B161","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4049\/jimmunol.127.1.347","article-title":"Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation","volume":"127","author":"Haynes","year":"1981","journal-title":"J Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1006\/bbrc.1999.1051","article-title":"Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98","volume":"262","author":"Hara","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B163","doi-asserted-by":"publisher","first-page":"54731","DOI":"10.1074\/jbc.M408700200","article-title":"CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation","volume":"279","author":"Henderson","year":"2004","journal-title":"J Biol Chem"},{"key":"B164","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/ni.1712","article-title":"CD98hc facilitates B cell proliferation and adaptive humoral immunity","volume":"10","author":"Cantor","year":"2009","journal-title":"Nat Immunol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"851","DOI":"10.4049\/jimmunol.1100002","article-title":"Loss of T cell CD98 H chain specifically ablates T cell clonal expansion and protects from autoimmunity","volume":"187","author":"Cantor","year":"2011","journal-title":"J Immunol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1242\/jcs.096040","article-title":"CD98 at the crossroads of adaptive immunity and cancer","volume":"125","author":"Cantor","year":"2012","journal-title":"J Cell Sci"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/leu.2014.338","article-title":"L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma\/T-cell acute lymphoblastic leukemia","volume":"29","author":"Rosilio","year":"2015","journal-title":"Leukemia"},{"key":"B168","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ijc.29415","article-title":"Antitumor activity of an anti-CD98 antibody","volume":"137","author":"Hayes","year":"2015","journal-title":"Int J Cancer"},{"key":"B169","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood.V126.23.3809.3809","article-title":"A phase I study of IGN523, a novel anti-CD98 monoclonal antibody in patients with relapsed or refractory acute myeloid leukemia (AML)","volume":"126","author":"Bixby","year":"2015","journal-title":"Blood"},{"key":"B170","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B171","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0609.2005.00436.x","article-title":"Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies","volume":"75","author":"Reichert","year":"2005","journal-title":"Eur J Haematol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-03-0627","article-title":"Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab","volume":"10","author":"Karp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/sj.leu.2404632","article-title":"Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity","volume":"21","author":"Zahiragic","year":"2007","journal-title":"Leukemia"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/blood-2009-06-230474","article-title":"Leukemia regression by vascular disruption and antiangiogenic therapy","volume":"116","author":"Madlambayan","year":"2010","journal-title":"Blood"},{"key":"B175","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1007\/s00018-011-0783-6","article-title":"Advances in tenascin-C biology","volume":"68","author":"Midwood","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B176","doi-asserted-by":"publisher","first-page":"201ra118","DOI":"10.1126\/scitranslmed.3006221","article-title":"Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia","volume":"5","author":"Gutbrodt","year":"2013","journal-title":"Sci Transl Med"},{"key":"B177","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/2326-6066.CIR-14-0179","article-title":"Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Schliemann","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B178","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood.V95.11.3289","article-title":"The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial\/stromal migration and engraftment of NOD\/SCID mice","volume":"95","author":"Peled","year":"2000","journal-title":"Blood"},{"key":"B179","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1182\/blood-2007-12-124818","article-title":"Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia","volume":"113","author":"Becker","year":"2009","journal-title":"Blood"},{"key":"B180","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1182\/blood.V122.21.3944.3944","article-title":"VLA4 blockade in acute myeloid leukemia","volume":"122","author":"Hsieh","year":"2013","journal-title":"Blood"},{"key":"B181","doi-asserted-by":"publisher","first-page":"e62785","DOI":"10.1371\/journal.pone.0062785","article-title":"TGF-beta-neutralizing antibody 1D11 enhances cytarabine-induced apoptosis in AML cells in the bone marrow microenvironment","volume":"8","author":"Tabe","year":"2013","journal-title":"PLoS One"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat Med"},{"key":"B183","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"B184","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B185","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2013.00496","article-title":"Dendritic cell-based immunotherapy for myeloid leukemias","volume":"4","author":"Sch\u00fcrch","year":"2013","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1182\/blood-2004-01-0064","article-title":"In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis","volume":"104","author":"Saudemont","year":"2004","journal-title":"Blood"},{"key":"B188","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"B189","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/eji.201242814","article-title":"Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands","volume":"43","author":"Dolen","year":"2013","journal-title":"Eur J Immunol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1084\/jem.20121229","article-title":"Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-gamma","volume":"210","author":"Sch\u00fcrch","year":"2013","journal-title":"J Exp Med"},{"key":"B191","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood.V98.13.3750","article-title":"Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment","volume":"98","author":"Mohty","year":"2001","journal-title":"Blood"},{"key":"B192","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1182\/blood-2008-05-156471","article-title":"Defective homing and impaired induction of cytotoxic T cells by BCR\/ABL-expressing dendritic cells","volume":"113","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"B193","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nrc3171","article-title":"Programmed cell removal: a new obstacle in the road to developing cancer","volume":"12","author":"Chao","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B194","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","author":"Boddu","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B196","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"},{"key":"B200","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B201","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B203","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B204","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2141.2006.06472.x","article-title":"CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis","volume":"136","author":"Laurent","year":"2007","journal-title":"Br J Haematol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF01715050","article-title":"Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution","volume":"67","author":"Vidriales","year":"1993","journal-title":"Ann Hematol"},{"key":"B206","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s00262-004-0505-0","article-title":"Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia","volume":"53","author":"Wendelbo","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"B207","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","article-title":"T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment","volume":"8","author":"Schnorfeil","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"key":"B209","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B210","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B211","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B212","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B214","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"B215","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"B216","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood-2009-12-255125","article-title":"Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes","volume":"116","author":"Kondo","year":"2010","journal-title":"Blood"},{"key":"B218","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kr\u00f6nig","year":"2014","journal-title":"Eur J Haematol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/leu.2015.26","article-title":"Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells","volume":"29","author":"Riether","year":"2015","journal-title":"Leukemia"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B221","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget"},{"key":"B222","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/leu.2016.328","article-title":"PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia","volume":"31","author":"Goltz","year":"2017","journal-title":"Leukemia"},{"key":"B223","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.coi.2006.09.009","article-title":"TIM-3 in autoimmunity","volume":"18","author":"Anderson","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cyto.2008.06.013","article-title":"TIM-1 and TIM-3 proteins in immune regulation","volume":"44","author":"Su","year":"2008","journal-title":"Cytokine"},{"key":"B225","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1158\/0008-5472.CAN-11-1487","article-title":"Prospects for TIM3-targeted antitumor immunotherapy","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"key":"B226","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","article-title":"Emerging Tim-3 functions in antimicrobial and tumor immunity","volume":"32","author":"Sakuishi","year":"2011","journal-title":"Trends Immunol"},{"key":"B227","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B228","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B229","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"B230","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/316354a0","article-title":"Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody","volume":"316","author":"Perez","year":"1985","journal-title":"Nature"},{"key":"B231","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/314628a0","article-title":"Hybrid antibodies can target sites for attack by T cells","volume":"314","author":"Staerz","year":"1985","journal-title":"Nature"},{"key":"B232","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"B233","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics","volume":"182","author":"Wu","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B234","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"key":"B236","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2014","journal-title":"Blood"},{"key":"B237","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nbt1216-1215","article-title":"Despite slow progress, bispecifics generate buzz","volume":"34","author":"Sheridan","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B238","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s40495-017-0090-5","article-title":"Pharmacokinetics of bispecific antibody","volume":"3","author":"Chen","year":"2017","journal-title":"Curr Pharmacol Rep"},{"key":"B239","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.V124.21.2316.2316","article-title":"Immunotherapy with long-lived anti-CD123\u00d7 anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia","volume":"124","author":"Chu","year":"2014","journal-title":"Blood"},{"key":"B240","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood.V128.22.2824.2824","article-title":"Development of a CD123xCD3 bispecific antibody (JNJ-63709178) for the treatment of acute myeloid leukemia (AML)","volume":"128","author":"Gaudet","year":"2016","journal-title":"Blood"},{"key":"B241","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1182\/blood.V128.22.2875.2875","article-title":"Ex vivo activity profile of the CD123xCD3 Duobody\u00ae antibody JNJ-63709178 against primary acute myeloid leukemia bone marrow samples","volume":"128","author":"Forslund","year":"2016","journal-title":"Blood"},{"key":"B242","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"key":"B243","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V126.23.325.325","article-title":"Preclinical evaluation of MCLA117, a CLEC12AxCD3 bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen in AML","volume":"126","author":"Van Loo","year":"2015","journal-title":"Blood"},{"key":"B244","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","article-title":"An anti-CD3\/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia","volume":"129","author":"Leong","year":"2017","journal-title":"Blood"},{"key":"B245","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"B246","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2011-02-337691","article-title":"DARTs take aim at BiTEs","volume":"117","author":"Rader","year":"2011","journal-title":"Blood"},{"key":"B247","doi-asserted-by":"publisher","first-page":"289ra282","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci Transl Med"},{"key":"B248","doi-asserted-by":"publisher","first-page":"TS7070","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7070","article-title":"A phase I, first-in-human study of MGD006\/S80880 (CD123 x CD3 DART) in AML\/MDS","volume":"35","author":"Vey","year":"2017","journal-title":"J Clin Oncol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1126\/science.274.5288.795","article-title":"Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice","volume":"274","author":"Lindberg","year":"1996","journal-title":"Science"},{"key":"B250","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol"},{"key":"B251","doi-asserted-by":"publisher","first-page":"40156","DOI":"10.1074\/jbc.M104138200","article-title":"The role of CD47 in neutrophil transmigration. Increased rate of migration correlates with increased cell surface expression of CD47","volume":"276","author":"Liu","year":"2001","journal-title":"J Biol Chem"},{"key":"B252","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1091\/mbc.E04-01-0019","article-title":"Promotion of neurite and filopodium formation by CD47: roles of integrins, Rac, and Cdc42","volume":"15","author":"Miyashita","year":"2004","journal-title":"Mol Biol Cell"},{"key":"B253","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"B254","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1084\/jem.194.4.541","article-title":"CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells","volume":"194","author":"Blazar","year":"2001","journal-title":"J Exp Med"},{"key":"B255","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","article-title":"Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte","volume":"123","author":"Gardai","year":"2005","journal-title":"Cell"},{"key":"B256","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1365-2141.2007.06729.x","article-title":"Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma","volume":"138","author":"Rendtlew Danielsen","year":"2007","journal-title":"Br J Haematol"},{"key":"B257","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"B258","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B259","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"B260","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res"},{"key":"B261","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","article-title":"Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood"},{"key":"B262","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1073\/pnas.1121629109","article-title":"Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma","volume":"109","author":"Edris","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B263","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B264","doi-asserted-by":"publisher","first-page":"e1373235","DOI":"10.1080\/2162402X.2017.1373235","article-title":"The \u201cdon\u2019t eat me\u201d signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma","volume":"7","author":"Sch\u00fcrch","year":"2017","journal-title":"Oncoimmunology"},{"key":"B265","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.cell.2009.04.064","article-title":"Exocytosis of post-Golgi vesicles is regulated by components of the endocytic machinery","volume":"137","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"B266","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.leukres.2015.04.007","article-title":"CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis","volume":"39","author":"Galli","year":"2015","journal-title":"Leuk Res"},{"key":"B267","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1038\/bcj.2017.7","article-title":"Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies","volume":"7","author":"Pietsch","year":"2017","journal-title":"Blood Cancer J"},{"key":"B268","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B269","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1182\/blood.V97.10.3132","article-title":"Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo","volume":"97","author":"Koh","year":"2001","journal-title":"Blood"},{"key":"B270","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B271","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","article-title":"Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value","volume":"110","author":"Ruggeri","year":"2007","journal-title":"Blood"},{"key":"B272","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"B273","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2009-02-206532","article-title":"Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells","volume":"114","author":"Romagne","year":"2009","journal-title":"Blood"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.tps3117","article-title":"Intergroup ALFA\/GOELAMS randomized phase II trial of lirilumab anti-KIR monoclonal antibody (IPH2102\/BMS986015) as maintenance treatment in elderly patients with acute myeloid leukemia (EFFIKIR trial)","author":"Vey","year":"2013","journal-title":"J Clin Oncol"},{"key":"B275","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1385\/IR:35:3:263","article-title":"The CD94\/NKG2 family of receptors: from molecules and cells to clinical relevance","volume":"35","author":"Borrego","year":"2006","journal-title":"Immunol Res"},{"key":"B276","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00251-002-0526-9","article-title":"Analysis of HLA-E expression in human tumors","volume":"54","author":"Marin","year":"2003","journal-title":"Immunogenetics"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-5666","article-title":"Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib\/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN)","author":"Cohen","year":"2017","journal-title":"Cancer Res"},{"key":"B278","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1182\/blood-2010-07-299248","article-title":"An anti-PR1\/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells","volume":"117","author":"Sergeeva","year":"2011","journal-title":"Blood"},{"key":"B279","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2016.57","article-title":"Activity of 8F4, a T-cell receptor-like anti-PR1\/HLA-A2 antibody, against primary human AML in vivo","volume":"30","author":"Sergeeva","year":"2016","journal-title":"Leukemia"},{"key":"B280","doi-asserted-by":"publisher","first-page":"176ra133","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody","volume":"5","author":"Dao","year":"2013","journal-title":"Sci Transl Med"},{"key":"B281","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","article-title":"A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias","volume":"123","author":"Dubrovsky","year":"2014","journal-title":"Blood"},{"key":"B282","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/ijc.25766","article-title":"In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA\u2019 in a human acute myeloid leukemia xenograft tumor model","volume":"129","author":"Tur","year":"2011","journal-title":"Int J Cancer"},{"key":"B283","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.dci.2003.09.016","article-title":"The interleukin 1 receptor family","volume":"28","author":"Subramaniam","year":"2004","journal-title":"Dev Comp Immunol"},{"key":"B284","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B285","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"Jaras","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B286","first-page":"4787","article-title":"IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients","volume":"7","author":"Zhao","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"B287","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/leu.2015.135","article-title":"IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome","volume":"30","author":"Landberg","year":"2016","journal-title":"Leukemia"},{"key":"B288","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","article-title":"Selective killing of candidate AML stem cells by antibody targeting of IL1RAP","volume":"121","author":"Askmyr","year":"2013","journal-title":"Blood"},{"key":"B289","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1073\/pnas.1422749112","article-title":"Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia","volume":"112","author":"Agerstam","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B290","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood.V79.8.1938.1938","article-title":"Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors","volume":"79","author":"Estrov","year":"1992","journal-title":"Blood"},{"key":"B291","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.semcancer.2006.07.002","article-title":"The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance","volume":"16","author":"Fuchs","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"B292","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","article-title":"Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)","volume":"172","author":"Fuchs","year":"2004","journal-title":"J Immunol"},{"key":"B293","first-page":"1209","article-title":"Antibodies TC-12 (\u201cunique\u201d) and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia","volume":"26","author":"Gramatzki","year":"1998","journal-title":"Exp Hematol"},{"key":"B294","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B295","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.arcmed.2014.04.001","article-title":"Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia","volume":"45","author":"Chavez-Gonzalez","year":"2014","journal-title":"Arch Med Res"},{"key":"B296","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.12659\/MSM.900305","article-title":"CD33, CD96 and death associated protein kinase (DAPK) expression are associated with the survival rate and\/or response to the chemotherapy in the patients with acute myeloid leukemia (AML)","volume":"23","author":"Jiang","year":"2017","journal-title":"Med Sci Monit"},{"key":"B297","doi-asserted-by":"publisher","first-page":"e42426","DOI":"10.1371\/journal.pone.0042426","article-title":"Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96","volume":"7","author":"Mohseni Nodehi","year":"2012","journal-title":"PLoS One"},{"key":"B298","first-page":"2283","article-title":"Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy","volume":"31","author":"Nassiri","year":"2011","journal-title":"Anticancer Res"},{"key":"B299","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1182\/blood-2017-01-763581","article-title":"Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models","volume":"129","author":"Dourado","year":"2017","journal-title":"Blood"},{"key":"B300","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0014-5793(94)01279-2","article-title":"ADP ribosyl cyclase activity of a novel bone marrow stromal cell surface molecule, BST-1","volume":"356","author":"Hirata","year":"1994","journal-title":"FEBS Lett"},{"key":"B301","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.1073\/pnas.91.12.5325","article-title":"BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth","volume":"91","author":"Kaisho","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B302","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1182\/blood-2004-06-2129","article-title":"CD157 is an important mediator of neutrophil adhesion and migration","volume":"104","author":"Funaro","year":"2004","journal-title":"Blood"},{"key":"B303","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1182\/blood-2006-04-017160","article-title":"CD157 plays a pivotal role in neutrophil transendothelial migration","volume":"108","author":"Ortolan","year":"2006","journal-title":"Blood"},{"key":"B304","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2741\/3287","article-title":"Ectoenzymes and innate immunity: the role of human CD157 in leukocyte trafficking","volume":"14","author":"Funaro","year":"2009","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B305","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000058772","article-title":"BST-1\/CD157 regulates the humoral immune responses in vivo","volume":"75","author":"Ishihara","year":"2000","journal-title":"Chem Immunol"},{"key":"B306","first-page":"964","article-title":"The modulated expression of Mo5, a human myelomonocytic plasma membrane antigen","volume":"65","author":"Todd","year":"1985","journal-title":"Blood"},{"key":"B307","doi-asserted-by":"publisher","first-page":"35707","DOI":"10.18632\/oncotarget.16060","article-title":"Targeting CD157 in AML using a novel, Fc-engineered antibody construct","volume":"8","author":"Krupka","year":"2017","journal-title":"Oncotarget"},{"key":"B308","first-page":"483","article-title":"CD200 and its receptors as targets for immunoregulation","volume":"6","author":"Gorczynski","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"B309","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/leu.2012.77","article-title":"Expression of CD200 on AML blasts directly suppresses memory T-cell function","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia"},{"key":"B310","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/leu.2015.62","article-title":"The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse","volume":"29","author":"Coles","year":"2015","journal-title":"Leukemia"},{"key":"B311","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/leu.2012.75","article-title":"Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia"},{"key":"B312","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s13277-012-0578-x","article-title":"Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia","volume":"34","author":"Memarian","year":"2013","journal-title":"Tumour Biol"},{"key":"B313","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"B314","doi-asserted-by":"publisher","first-page":"110350","DOI":"10.18632\/oncotarget.22739","article-title":"High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation","volume":"8","author":"Farag","year":"2017","journal-title":"Oncotarget"},{"key":"B315","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B316","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/bloodadvances.2017008342","article-title":"Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice","volume":"1","author":"Gillissen","year":"2017","journal-title":"Blood Adv"},{"key":"B317","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/leu.2011.36","article-title":"CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression","volume":"25","author":"Saito","year":"2011","journal-title":"Leukemia"},{"key":"B318","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-13-2811","article-title":"Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML","volume":"20","author":"Blatt","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B319","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/cam4.482","article-title":"Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo","volume":"4","author":"Nishioka","year":"2015","journal-title":"Cancer Med"},{"key":"B320","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.stem.2015.08.008","article-title":"CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia","volume":"17","author":"Iwasaki","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B321","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood.V124.21.2309.2309","article-title":"Development and preclinical characterization of an Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia","volume":"124","author":"Koerner","year":"2014","journal-title":"Blood"},{"key":"B322","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood.V126.23.3793.3793","article-title":"Induction of NK cell reactivity against myeloid leukemia by a novel Fc-optimized CD133 antibody","volume":"126","author":"Rothfelder","year":"2015","journal-title":"Blood"},{"key":"B323","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/2326-6066.CIR-17-0212","article-title":"The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia","volume":"6","author":"Nuebling","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B324","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/mt.2015.2","article-title":"Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia","volume":"23","author":"Durben","year":"2015","journal-title":"Mol Ther"},{"key":"B325","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood-2009-06-227934","article-title":"CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells","volume":"115","author":"Baessler","year":"2010","journal-title":"Blood"},{"key":"B326","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/bjh.12732","article-title":"CD137 ligand signalling induces differentiation of primary acute myeloid leukaemia cells","volume":"165","author":"Cheng","year":"2014","journal-title":"Br J Haematol"},{"key":"B327","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1136\/jim-2016-000081","article-title":"Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML","volume":"64","author":"Schmohl","year":"2016","journal-title":"J Investig Med"},{"key":"B328","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2051-1426-1-13","article-title":"Immune evasion in acute myeloid leukemia: current concepts and future directions","volume":"1","author":"Teague","year":"2013","journal-title":"J Immunother Cancer"},{"key":"B329","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"B330","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/imm.12665","article-title":"Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells","volume":"149","author":"Ozkazanc","year":"2016","journal-title":"Immunology"},{"key":"B331","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/leu.2009.99","article-title":"Monoclonal antibodies against IREM-1: potential for targeted therapy of AML","volume":"23","author":"Korver","year":"2009","journal-title":"Leukemia"},{"key":"B332","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1756-9966-31-92","article-title":"Inhibition of the ecto-beta subunit of F1F0-ATPase inhibits proliferation and induces apoptosis in acute myeloid leukemia cell lines","volume":"31","author":"Wen-Li","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"B333","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/0008-5472.CAN-08-2650","article-title":"Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans","volume":"69","author":"Baessler","year":"2009","journal-title":"Cancer Res"},{"key":"B334","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.coi.2011.12.011","article-title":"Modulation of GITR for cancer immunotherapy","volume":"24","author":"Schaer","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B335","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/mt.2013.11","article-title":"Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia","volume":"21","author":"Schmiedel","year":"2013","journal-title":"Mol Ther"},{"key":"B336","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00262-008-0567-5","article-title":"Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies","volume":"58","author":"Drake","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B337","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1038\/bcj.2015.39","article-title":"A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies","volume":"5","author":"Kim","year":"2015","journal-title":"Blood Cancer J"},{"key":"B338","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B339","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/blood-2017-02-768762","article-title":"AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses","volume":"131","author":"Gillissen","year":"2018","journal-title":"Blood"},{"key":"B340","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood.V128.22.4056.4056","article-title":"Enhanced VISTA expression in a subset of patients with acute myeloid leukemia","volume":"128","author":"Lamble","year":"2016","journal-title":"Blood"},{"key":"B341","first-page":"2658","article-title":"PD-1H (VISTA) induces immune evasion in acute myeloid leukemia","volume":"130","author":"Kim","year":"2017","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T18:14:32Z","timestamp":1693678472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":341,"alternative-id":["10.3389\/fonc.2018.00152"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00152","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]},"article-number":"152"}}